The risk or severity of adverse effects can be increased when epinephrine is combined with PROCATEROL.


The risk or severity of adverse effects can be increased when trandolapril is combined with indapamide.


The risk or severity of adverse effects can be increased when lisinopril is combined with sulindac.


The risk or severity of adverse effects can be increased when Butethal is combined with clemastine.


The risk or severity of adverse effects can be increased when triflupromazine is combined with thiopental.


The risk or severity of adverse effects can be increased when Butethal is combined with venlafaxine.


The risk or severity of adverse effects can be increased when ondansetron is combined with Etidocaine.


The risk or severity of adverse effects can be increased when cilnidipine is combined with Coenzyme Q10.


The risk or severity of adverse effects can be increased when Articaine is combined with Pizotifen.


The risk or severity of adverse effects can be increased when propofol is combined with Ethylmorphine.


The risk or severity of adverse effects can be increased when chloral hydrate is combined with Ramelteon.


The risk or severity of adverse effects can be increased when levorphanol is combined with Drospirenone.


The risk or severity of adverse effects can be increased when tioconazole is combined with atorvastatin.


The risk or severity of adverse effects can be increased when chloral hydrate is combined with DIMENHYDRINATE.


The risk or severity of adverse effects can be increased when meclizine is combined with BREXPIPRAZOLE.


The risk or severity of adverse effects can be increased when droperidol is combined with metoclopramide.


The risk or severity of adverse effects can be increased when MORICIZINE is combined with nefazodone.


The risk or severity of adverse effects can be increased when reserpine is combined with etizolam.


The risk or severity of adverse effects can be increased when METHOHEXITAL is combined with METAXALONE.


The risk or severity of adverse effects can be increased when fexofenadine is combined with BREXPIPRAZOLE.


The risk or severity of adverse effects can be increased when morphine is combined with penbutolol.


The risk or severity of adverse effects can be increased when ethotoin is combined with desipramine.


The risk or severity of adverse effects can be increased when morphine is combined with Hexobarbital.


The risk or severity of adverse effects can be increased when morphine is combined with lithium ion.


The risk or severity of adverse effects can be increased when morphine is combined with amobarbital.


The risk or severity of adverse effects can be increased when morphine is combined with Butethal.


The risk or severity of adverse effects can be increased when SUFENTANIL is combined with furosemide.


The risk or severity of adverse effects can be increased when rasagiline is combined with Bambuterol.


The risk or severity of adverse effects can be increased when chloroquine is combined with salicylic acid.


The risk or severity of adverse effects can be increased when etizolam is combined with carisoprodol.


The risk or severity of adverse effects can be increased when lorazepam is combined with zotepine.


The risk or severity of adverse effects can be increased when rasagiline is combined with Levomepromazine.


The risk or severity of adverse effects can be increased when Paricalcitol is combined with dihydrotachysterol.


The risk or severity of adverse effects can be increased when clomipramine is combined with nilvadipine.


The risk or severity of adverse effects can be increased when rasagiline is combined with clenbuterol.


The risk or severity of adverse effects can be increased when diclofenac is combined with PIRFENIDONE.


The risk or severity of adverse effects can be increased when enflurane is combined with desipramine.


The risk or severity of adverse effects can be increased when terconazole is combined with Rosuvastatin.


The risk or severity of adverse effects can be increased when pramipexole is combined with carvedilol.


The risk or severity of adverse effects can be increased when Eszopiclone is combined with nalbuphine.


The risk or severity of adverse effects can be increased when nitroglycerin is combined with ETHACRYNIC ACID.


The risk or severity of adverse effects can be increased when Lornoxicam is combined with formestane.


The risk or severity of adverse effects can be increased when nalbuphine is combined with Fospropofol.


The risk or severity of adverse effects can be increased when triamterene is combined with trandolapril.


The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Etidocaine.


The risk or severity of adverse effects can be increased when Metipranolol is combined with AZILSARTAN MEDOXOMIL.


The risk or severity of adverse effects can be increased when papaverine is combined with acebutolol.


The risk or severity of adverse effects can be increased when Dothiepin is combined with isoetharine.


The risk or severity of adverse effects can be increased when metolazone is combined with labetalol.


The risk or severity of adverse effects can be increased when baclofen is combined with scopolamine.


The risk or severity of adverse effects can be increased when Fluspirilene is combined with meclizine.


The risk or severity of adverse effects can be increased when chloral hydrate is combined with oxprenolol.


The risk or severity of adverse effects can be increased when ILOPROST is combined with nitric oxide.


The risk or severity of adverse effects can be increased when chlormezanone is combined with Ramelteon.


The risk or severity of adverse effects can be increased when metolazone is combined with doxazosin.


The risk or severity of adverse effects can be increased when Tramadol is combined with bromazepam.


The risk or severity of adverse effects can be increased when chlormezanone is combined with DIMENHYDRINATE.


The risk or severity of adverse effects can be increased when citric acid is combined with Deferasirox.


The risk or severity of adverse effects can be increased when chloral hydrate is combined with prazepam.


The risk or severity of adverse effects can be increased when bupivacaine is combined with DEXMEDETOMIDINE.


The risk or severity of adverse effects can be increased when butalbital is combined with Desloratadine.


The risk or severity of adverse effects can be increased when chlorothiazide is combined with Riociguat.


The risk or severity of adverse effects can be increased when cilazapril is combined with PIRFENIDONE.


The risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipamperone.


The risk or severity of adverse effects can be increased when LISURIDE is combined with risperidone.


The risk or severity of adverse effects can be increased when codeine is combined with levorphanol.


The risk or severity of adverse effects can be increased when enflurane is combined with trazodone.


The risk or severity of adverse effects can be increased when clomipramine is combined with mecamylamine.


The risk or severity of adverse effects can be increased when triprolidine is combined with sertraline.


The risk or severity of adverse effects can be increased when dyclonine is combined with glutethimide.


The risk or severity of adverse effects can be increased when Almotriptan is combined with Frovatriptan.


The risk or severity of adverse effects can be increased when sulpiride is combined with tetracaine.


The risk or severity of adverse effects can be increased when zaleplon is combined with Perospirone.


The risk or severity of adverse effects can be increased when rapamycin is combined with leflunomide.


The risk or severity of adverse effects can be increased when thalidomide is combined with ETHACRYNIC ACID.


The risk or severity of adverse effects can be increased when reserpine is combined with KETAZOLAM.


The risk or severity of adverse effects can be increased when nimesulide is combined with CLOCORTOLONE.


The risk or severity of adverse effects can be increased when TAMSULOSIN is combined with Candesartan cilexetil.


The risk or severity of adverse effects can be increased when TAMSULOSIN is combined with tolazoline.


The risk or severity of adverse effects can be increased when chlorthalidone is combined with nicardipine.


The risk or severity of adverse effects can be increased when mefenamic acid is combined with hydrocortisone.


The risk or severity of adverse effects can be increased when ropinirole is combined with benazepril.


The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butethal.


The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hexobarbital.


The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with lithium ion.


The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with etizolam.


The risk or severity of adverse effects can be increased when Oxetacaine is combined with Lormetazepam.


The risk or severity of adverse effects can be increased when zolmitriptan is combined with isocarboxazid.


The risk or severity of adverse effects can be increased when lisinopril is combined with Empagliflozin.


The risk or severity of adverse effects can be increased when bupivacaine is combined with VORTIOXETINE.


The risk or severity of adverse effects can be increased when isocarboxazid is combined with Pipamperone.


The risk or severity of adverse effects can be increased when ethyl loflazepate is combined with phenytoin.


The risk or severity of adverse effects can be increased when amiodarone is combined with pramipexole.


The risk or severity of adverse effects can be increased when pramipexole is combined with ropinirole.


The risk or severity of adverse effects can be increased when Fencamfamin is combined with Olopatadine.


The risk or severity of adverse effects can be increased when glutethimide is combined with MELPERONE.


The risk or severity of adverse effects can be increased when pramipexole is combined with metoprolol.


The risk or severity of adverse effects can be increased when oxycodone is combined with ethyl loflazepate.


The risk or severity of adverse effects can be increased when oxycodone is combined with flunitrazepam.


The risk or severity of adverse effects can be increased when proparacaine is combined with methoxyflurane.


The risk or severity of adverse effects can be increased when amobarbital is combined with HEROIN.


The risk or severity of adverse effects can be increased when sertraline is combined with ACETOPHENAZINE.


The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with tiapride.


The risk or severity of adverse effects can be increased when quetiapine is combined with triflupromazine.


The risk or severity of adverse effects can be increased when flurandrenolide is combined with edrophonium.


The risk or severity of adverse effects can be increased when carprofen is combined with FLUTICASONE PROPIONATE.


The risk or severity of adverse effects can be increased when ondansetron is combined with Butethal.


The risk or severity of adverse effects can be increased when trifluoperazine is combined with gabapentin.


The risk or severity of adverse effects can be increased when ondansetron is combined with Hexobarbital.


The risk or severity of adverse effects can be increased when tiaprofenic acid is combined with Risedronic acid.


The risk or severity of adverse effects can be increased when MAGNESIUM SULFATE is combined with pravastatin.


The risk or severity of adverse effects can be increased when Milnacipran is combined with tiapride.


The risk or severity of adverse effects can be increased when Dothiepin is combined with Escitalopram.


The risk or severity of adverse effects can be increased when dihydroergotamine is combined with amisulpride.


The risk or severity of adverse effects can be increased when bromazepam is combined with flunarizine.


The risk or severity of adverse effects can be increased when nicergoline is combined with danazol.


The risk or severity of adverse effects can be increased when D-mannitol is combined with Metipranolol.


The risk or severity of adverse effects can be increased when D-mannitol is combined with LEVOBUNOLOL.


The risk or severity of adverse effects can be increased when bepridil is combined with Bortezomib.


The risk or severity of adverse effects can be increased when bepridil is combined with ESMOLOL.


The risk or severity of adverse effects can be increased when labetalol is combined with ritodrine.


The risk or severity of adverse effects can be increased when Bortezomib is combined with Lofexidine.


The risk or severity of adverse effects can be increased when bupivacaine is combined with MELPERONE.


The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronic Acid.


The risk or severity of adverse effects can be increased when perphenazine is combined with Pizotifen.


The risk or severity of adverse effects can be increased when MELPERONE is combined with ethosuximide.


The risk or severity of adverse effects can be increased when Isoconazole is combined with nimesulide.


The risk or severity of adverse effects can be increased when sevoflurane is combined with betaxolol.


The risk or severity of adverse effects can be increased when FLUTICASONE PROPIONATE is combined with GALLAMINE TRIETHIODIDE.


The risk or severity of adverse effects can be increased when pancuronium is combined with ALFENTANIL.


The risk or severity of adverse effects can be increased when FLUTICASONE PROPIONATE is combined with Pefloxacin.


The risk or severity of adverse effects can be increased when BENZYDAMINE is combined with haloperidol.


The risk or severity of adverse effects can be increased when CORTISONE ACETATE is combined with Gatifloxacin.


The risk or severity of adverse effects can be increased when dibucaine is combined with flunitrazepam.


The risk or severity of adverse effects can be increased when rivastigmine is combined with methacholine.


The risk or severity of adverse effects can be increased when CORTISONE ACETATE is combined with memantine.


The risk or severity of adverse effects can be increased when carbamazepine is combined with METAXALONE.


The risk or severity of adverse effects can be increased when dipyridamole is combined with irbesartan.


The risk or severity of adverse effects can be increased when oxybutynin is combined with Metixene.


The risk or severity of adverse effects can be increased when dipyridamole is combined with felodipine.


The risk or severity of adverse effects can be increased when 5-Fluorocytosine is combined with eperisone.


The risk or severity of adverse effects can be increased when nelfinavir is combined with meperidine.


The risk or severity of adverse effects can be increased when Metixene is combined with Methadyl acetate.


The risk or severity of adverse effects can be increased when Pramocaine is combined with Oxetacaine.


The risk or severity of adverse effects can be increased when zaltoprofen is combined with triamcinolone.


The risk or severity of adverse effects can be increased when HEROIN is combined with KETAZOLAM.


The risk or severity of adverse effects can be increased when halothane is combined with ramipril.


The risk or severity of adverse effects can be increased when meperidine is combined with propoxyphene.


The risk or severity of adverse effects can be increased when CARTEOLOL is combined with LEVOBUNOLOL.


The risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.


The risk or severity of adverse effects can be increased when MELPERONE is combined with CYCLIZINE.


The risk or severity of adverse effects can be increased when Phenelzine is combined with terbutaline.


The risk or severity of adverse effects can be increased when apomorphine is combined with Bortezomib.


The risk or severity of adverse effects can be increased when etodolac is combined with medrysone.


The risk or severity of adverse effects can be increased when rescinnamine is combined with nimesulide.


The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with felbamate.


The risk or severity of adverse effects can be increased when Lormetazepam is combined with duloxetine.


The risk or severity of adverse effects can be increased when ALFENTANIL is combined with indapamide.


The risk or severity of adverse effects can be increased when indapamide is combined with Empagliflozin.


The risk or severity of adverse effects can be increased when ALFENTANIL is combined with proparacaine.


The risk or severity of adverse effects can be increased when HEROIN is combined with oxprenolol.


The risk or severity of adverse effects can be increased when ALFENTANIL is combined with Halazepam.


The risk or severity of adverse effects can be increased when morniflumate is combined with carprofen.


The risk or severity of adverse effects can be increased when valsartan is combined with sotalol.


The risk or severity of adverse effects can be increased when Asenapine is combined with Ketobemidone.


The risk or severity of adverse effects can be increased when gabapentin is combined with CYCLIZINE.


The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with cilazapril.


The risk or severity of adverse effects can be increased when ZILEUTON is combined with Fluprednidene.


The risk or severity of adverse effects can be increased when Remoxipride is combined with oxprenolol.


The risk or severity of adverse effects can be increased when morphine is combined with Aliskiren.


The risk or severity of adverse effects can be increased when betaxolol is combined with pilocarpine.


The risk or severity of adverse effects can be increased when ethyl loflazepate is combined with Aceprometazine.


The risk or severity of adverse effects can be increased when acemetacin is combined with DESONIDE.


The risk or severity of adverse effects can be increased when risperidone is combined with nitrazepam.


The risk or severity of adverse effects can be increased when Torasemide is combined with Nitroprusside.


The risk or severity of adverse effects can be increased when prilocaine is combined with sertraline.


The risk or severity of adverse effects can be increased when fosinopril is combined with resveratrol.


The risk or severity of adverse effects can be increased when PROCATEROL is combined with isoxsuprine.


The risk or severity of adverse effects can be increased when 4-Hydroxybutanoic acid is combined with Asenapine.


The risk or severity of adverse effects can be increased when pentazocine is combined with Dexbrompheniramine.


The risk or severity of adverse effects can be increased when arsenic trioxide is combined with nadolol.


The risk or severity of adverse effects can be increased when Sacubitril is combined with Clevidipine.


The risk or severity of adverse effects can be increased when floctafenine is combined with estrone.


The risk or severity of adverse effects can be increased when flurazepam is combined with Iloperidone.


The risk or severity of adverse effects can be increased when clozapine is combined with thiamylal.


The risk or severity of adverse effects can be increased when naratriptan is combined with Paliperidone.


The risk or severity of adverse effects can be increased when pentazocine is combined with Remoxipride.


The risk or severity of adverse effects can be increased when DESFLURANE is combined with Remoxipride.


The risk or severity of adverse effects can be increased when propofol is combined with chloral hydrate.


The risk or severity of adverse effects can be increased when diclofenac is combined with CLOCORTOLONE.


The risk or severity of adverse effects can be increased when UMECLIDINIUM is combined with levorphanol.


The risk or severity of adverse effects can be increased when DESFLURANE is combined with nisoldipine.


The risk or severity of adverse effects can be increased when fosinopril is combined with DEXMEDETOMIDINE.


The risk or severity of adverse effects can be increased when DESFLURANE is combined with Dexbrompheniramine.


The risk or severity of adverse effects can be increased when PREDNICARBATE is combined with Demecarium.


The risk or severity of adverse effects can be increased when nitrazepam is combined with Retigabine.


The risk or severity of adverse effects can be increased when Loxoprofen is combined with fluocinonide.


The risk or severity of adverse effects can be increased when etodolac is combined with suprofen.


The risk or severity of adverse effects can be increased when etodolac is combined with loteprednol.


The risk or severity of adverse effects can be increased when temazepam is combined with levodopa.


The risk or severity of adverse effects can be increased when temazepam is combined with sevoflurane.


The risk or severity of adverse effects can be increased when benzyl alcohol is combined with Retigabine.


The risk or severity of adverse effects can be increased when pentobarbital is combined with Retigabine.


The risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.


The risk or severity of adverse effects can be increased when QUINETHAZONE is combined with digoxin.


The risk or severity of adverse effects can be increased when QUINETHAZONE is combined with sulpiride.


The risk or severity of adverse effects can be increased when Trospium is combined with meperidine.


The risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.


The risk or severity of adverse effects can be increased when carbamazepine is combined with DEZOCINE.


The risk or severity of adverse effects can be increased when CABAZITAXEL is combined with leflunomide.


The risk or severity of adverse effects can be increased when temazepam is combined with amoxapine.


The risk or severity of adverse effects can be increased when VALPROIC ACID is combined with triflupromazine.


The risk or severity of adverse effects can be increased when REMIFENTANIL is combined with ISOSORBIDE MONONITRATE.


The risk or severity of adverse effects can be increased when carbamazepine is combined with Levetiracetam.


The risk or severity of adverse effects can be increased when loxapine is combined with ketamine.


The risk or severity of adverse effects can be increased when Hexobarbital is combined with Articaine.


The risk or severity of adverse effects can be increased when pentazocine is combined with tizanidine.


The risk or severity of adverse effects can be increased when sulfasalazine is combined with acemetacin.


The risk or severity of adverse effects can be increased when indapamide is combined with acetyldigitoxin.


The risk or severity of adverse effects can be increased when ipratropium is combined with buprenorphine.


The risk or severity of adverse effects can be increased when enflurane is combined with Mephobarbital.


The risk or severity of adverse effects can be increased when Tramadol is combined with zonisamide.


The risk or severity of adverse effects can be increased when cilostazol is combined with TROLAMINE SALICYLATE.


The risk or severity of adverse effects can be increased when antipyrine is combined with niflumic acid.


The risk or severity of adverse effects can be increased when Tramadol is combined with ETHACRYNIC ACID.


The risk or severity of adverse effects can be increased when Articaine is combined with paroxetine.


The risk or severity of adverse effects can be increased when flunitrazepam is combined with Levomilnacipran.


The risk or severity of adverse effects can be increased when Tramadol is combined with tiagabine.


The risk or severity of adverse effects can be increased when chlordiazepoxide is combined with MOLINDONE.


The risk or severity of adverse effects can be increased when diltiazem is combined with ISOSORBIDE DINITRATE.


The risk or severity of adverse effects can be increased when risperidone is combined with butalbital.


The risk or severity of adverse effects can be increased when trifluoperazine is combined with fludiazepam.


The risk or severity of adverse effects can be increased when methylene blue is combined with hydromorphone.


The risk or severity of adverse effects can be increased when trifluoperazine is combined with chloral hydrate.


The risk or severity of adverse effects can be increased when lithium ion is combined with tetracaine.


The risk or severity of adverse effects can be increased when isradipine is combined with BENDROFLUMETHIAZIDE.


The risk or severity of adverse effects can be increased when ATROPINE is combined with codeine.


The risk or severity of adverse effects can be increased when bupivacaine is combined with Carbetocin.


The risk or severity of adverse effects can be increased when nitrous oxide is combined with Iloperidone.


The risk or severity of adverse effects can be increased when epirizole is combined with flumethasone.


The risk or severity of adverse effects can be increased when Hexobarbital is combined with prazepam.


The risk or severity of adverse effects can be increased when Tedizolid phosphate is combined with clozapine.


The risk or severity of adverse effects can be increased when methylergonovine is combined with nitric oxide.


The risk or severity of adverse effects can be increased when butabarbital is combined with quazepam.


The risk or severity of adverse effects can be increased when butabarbital is combined with prazepam.


The risk or severity of adverse effects can be increased when Sacubitril is combined with doxazosin.


The risk or severity of adverse effects can be increased when ketamine is combined with clonidine.


The risk or severity of adverse effects can be increased when Rotigotine is combined with indapamide.


The risk or severity of adverse effects can be increased when MOXONIDINE is combined with REMIFENTANIL.


The risk or severity of adverse effects can be increased when morphine is combined with oxazepam.


The risk or severity of adverse effects can be increased when tolfenamic acid is combined with RIMEXOLONE.


The risk or severity of adverse effects can be increased when morniflumate is combined with BALSALAZIDE.


The risk or severity of adverse effects can be increased when codeine is combined with levodopa.


The risk or severity of adverse effects can be increased when oxazepam is combined with Ropivacaine.


The risk or severity of adverse effects can be increased when oxazepam is combined with bupivacaine.


The risk or severity of adverse effects can be increased when KETAZOLAM is combined with MOLINDONE.


The risk or severity of adverse effects can be increased when benzocaine is combined with levodopa.


The risk or severity of adverse effects can be increased when pentazocine is combined with Methylnaltrexone.


The risk or severity of adverse effects can be increased when AZILSARTAN MEDOXOMIL is combined with BALSALAZIDE.


The risk or severity of adverse effects can be increased when prilocaine is combined with Olopatadine.


The risk or severity of adverse effects can be increased when Almotriptan is combined with pimozide.


The risk or severity of adverse effects can be increased when Almotriptan is combined with sertraline.


The risk or severity of adverse effects can be increased when sulpiride is combined with fexofenadine.


The risk or severity of adverse effects can be increased when ibuprofen is combined with Lumiracoxib.


The risk or severity of adverse effects can be increased when codeine is combined with Aripiprazole.


The risk or severity of adverse effects can be increased when linezolid is combined with bromocriptine.


The risk or severity of adverse effects can be increased when pergolide is combined with CORTISONE ACETATE.


The risk or severity of adverse effects can be increased when nisoldipine is combined with hydralazine.


The risk or severity of adverse effects can be increased when ALFENTANIL is combined with QUINETHAZONE.


The risk or severity of adverse effects can be increased when pentazocine is combined with Fencamfamin.


The risk or severity of adverse effects can be increased when irinotecan is combined with clozapine.


The risk or severity of adverse effects can be increased when THYMOL is combined with nisoldipine.


The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with scopolamine.


The risk or severity of adverse effects can be increased when ALFENTANIL is combined with polythiazide.


The risk or severity of adverse effects can be increased when Eszopiclone is combined with midazolam.


The risk or severity of adverse effects can be increased when indomethacin is combined with Propacetamol.


The risk or severity of adverse effects can be increased when bupivacaine is combined with quinapril.


The risk or severity of adverse effects can be increased when loxapine is combined with fluvoxamine.


The risk or severity of adverse effects can be increased when bupivacaine is combined with ISOSORBIDE DINITRATE.


The risk or severity of adverse effects can be increased when maprotiline is combined with BREXPIPRAZOLE.


The risk or severity of adverse effects can be increased when Hexobarbital is combined with baclofen.


The risk or severity of adverse effects can be increased when bupivacaine is combined with bumetanide.


The risk or severity of adverse effects can be increased when Sacubitril is combined with atenolol.


The risk or severity of adverse effects can be increased when glutethimide is combined with venlafaxine.


The risk or severity of adverse effects can be increased when Sacubitril is combined with Pimecrolimus.


The risk or severity of adverse effects can be increased when tolterodine is combined with Methylscopolamine bromide.


The risk or severity of adverse effects can be increased when Azelnidipine is combined with lovastatin.


The risk or severity of adverse effects can be increased when triazolam is combined with MOLINDONE.


The risk or severity of adverse effects can be increased when glutethimide is combined with clemastine.


The risk or severity of adverse effects can be increased when midazolam is combined with fexofenadine.


The risk or severity of adverse effects can be increased when Lercanidipine is combined with AZILSARTAN MEDOXOMIL.


The risk or severity of adverse effects can be increased when CARTEOLOL is combined with hydrochlorothiazide.


The risk or severity of adverse effects can be increased when TRICHLOROETHYLENE is combined with maprotiline.


The risk or severity of adverse effects can be increased when butabarbital is combined with baclofen.


The risk or severity of adverse effects can be increased when ramipril is combined with Lornoxicam.


The risk or severity of adverse effects can be increased when doxylamine is combined with paroxetine.


The risk or severity of adverse effects can be increased when triflupromazine is combined with clidinium.


The risk or severity of adverse effects can be increased when butabarbital is combined with ethchlorvynol.


The risk or severity of adverse effects can be increased when prazosin is combined with nicardipine.


The risk or severity of adverse effects can be increased when reserpine is combined with cilazapril.


The risk or severity of adverse effects can be increased when Clofarabine is combined with MOEXIPRIL.


The risk or severity of adverse effects can be increased when DESFLURANE is combined with LEVOBUNOLOL.


The risk or severity of adverse effects can be increased when pentazocine is combined with procaine.


The risk or severity of adverse effects can be increased when Toloxatone is combined with dipivefrin.


The risk or severity of adverse effects can be increased when clozapine is combined with CYPROHEPTADINE.


The risk or severity of adverse effects can be increased when clozapine is combined with nitric oxide.


The risk or severity of adverse effects can be increased when clozapine is combined with BENDROFLUMETHIAZIDE.


The risk or severity of adverse effects can be increased when Caspofungin is combined with Lercanidipine.


The risk or severity of adverse effects can be increased when Nebivolol is combined with Riociguat.


The risk or severity of adverse effects can be increased when Nepafenac is combined with carprofen.


The risk or severity of adverse effects can be increased when butamben is combined with Levocetirizine.


The risk or severity of adverse effects can be increased when ethanol is combined with venlafaxine.


The risk or severity of adverse effects can be increased when estazolam is combined with Aripiprazole.


The risk or severity of adverse effects can be increased when estazolam is combined with chlorprothixene.


The risk or severity of adverse effects can be increased when Atracurium besylate is combined with DIPHENOXYLATE.


The risk or severity of adverse effects can be increased when estazolam is combined with sevoflurane.


The risk or severity of adverse effects can be increased when floctafenine is combined with dexamethasone.


The risk or severity of adverse effects can be increased when quinapril is combined with Pregabalin.


The risk or severity of adverse effects can be increased when epinephrine is combined with oxymetazoline.


The risk or severity of adverse effects can be increased when thioridazine is combined with butalbital.


The risk or severity of adverse effects can be increased when DEZOCINE is combined with primidone.


The risk or severity of adverse effects can be increased when etodolac is combined with Magnesium salicylate.


The risk or severity of adverse effects can be increased when TRICHLOROETHYLENE is combined with Iloperidone.


The risk or severity of adverse effects can be increased when thiopental is combined with Perospirone.


The risk or severity of adverse effects can be increased when tolfenamic acid is combined with Etidronic acid.


The risk or severity of adverse effects can be increased when tolfenamic acid is combined with atorvastatin.


The risk or severity of adverse effects can be increased when etodolac is combined with Salsalate.


The risk or severity of adverse effects can be increased when Sacubitril is combined with labetalol.


The risk or severity of adverse effects can be increased when tenoxicam is combined with desoximetasone.


The risk or severity of adverse effects can be increased when Limaprost is combined with EDTA.


The risk or severity of adverse effects can be increased when Limaprost is combined with dipyridamole.


The risk or severity of adverse effects can be increased when Apremilast is combined with haloperidol.


The risk or severity of adverse effects can be increased when scopolamine is combined with pirenzepine.


The risk or severity of adverse effects can be increased when DEZOCINE is combined with methocarbamol.


The risk or severity of adverse effects can be increased when scopolamine is combined with Retigabine.


The risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat.


The risk or severity of adverse effects can be increased when sevoflurane is combined with Pipamperone.


The risk or severity of adverse effects can be increased when Propiverine is combined with Tapentadol.


The risk or severity of adverse effects can be increased when quinapril is combined with salicylamide.


The risk or severity of adverse effects can be increased when indomethacin is combined with mefenamic acid.


The risk or severity of adverse effects can be increased when Ziprasidone is combined with cetirizine.


The risk or severity of adverse effects can be increased when Remoxipride is combined with methylphenidate.


The risk or severity of adverse effects can be increased when cyclobenzaprine is combined with butalbital.


The risk or severity of adverse effects can be increased when Remoxipride is combined with triprolidine.


The risk or severity of adverse effects can be increased when ethyl loflazepate is combined with maprotiline.


The risk or severity of adverse effects can be increased when carisoprodol is combined with Retigabine.


The risk or severity of adverse effects can be increased when cyclopentolate is combined with meperidine.


The risk or severity of adverse effects can be increased when DEZOCINE is combined with spironolactone.


The risk or severity of adverse effects can be increased when CABAZITAXEL is combined with irinotecan.


The risk or severity of adverse effects can be increased when phentolamine is combined with spironolactone.


The risk or severity of adverse effects can be increased when Triflusal is combined with Apixaban.


The risk or severity of adverse effects can be increased when DEZOCINE is combined with triprolidine.


The risk or severity of heart failure can be increased when Pregabalin is combined with voglibose.


The risk or severity of heart failure can be increased when Pregabalin is combined with tolbutamide.


The risk or severity of heart failure can be increased when Pregabalin is combined with Canagliflozin.


The risk or severity of heart failure can be increased when Pregabalin is combined with Alogliptin.


The risk or severity of heart failure can be increased when Pregabalin is combined with nateglinide.


The risk or severity of heart failure can be increased when Pregabalin is combined with Sitagliptin.


The risk or severity of heart failure can be increased when Pregabalin is combined with Empagliflozin.


The risk or severity of heart failure can be increased when Pregabalin is combined with Pioglitazone.


The risk or severity of heart failure can be increased when Pregabalin is combined with glyburide.


The risk or severity of heart failure can be increased when Pregabalin is combined with Vildagliptin.


The risk or severity of heart failure can be increased when Pregabalin is combined with MIGLITOL.


The risk or severity of heart failure can be increased when Pregabalin is combined with gliclazide.


The risk or severity of heart failure can be increased when Pregabalin is combined with Saxagliptin.


The risk or severity of heart failure can be increased when Pregabalin is combined with acarbose.


The risk or severity of heart failure can be increased when Pregabalin is combined with metformin.


The risk or severity of heart failure can be increased when Pregabalin is combined with tolazamide.


The risk or severity of heart failure can be increased when Pregabalin is combined with Miglustat.


The risk or severity of heart failure can be increased when Pregabalin is combined with Repaglinide.


The risk or severity of heart failure can be increased when Pregabalin is combined with glipizide.


The risk or severity of heart failure can be increased when Pregabalin is combined with Gliquidone.


The risk or severity of heart failure can be increased when Pregabalin is combined with Linagliptin.


The risk or severity of heart failure can be increased when Pregabalin is combined with chlorpropamide.


The risk or severity of heart failure can be increased when Pregabalin is combined with glimepiride.


The risk or severity of heart failure can be increased when Pregabalin is combined with rosiglitazone.


dihydrotachysterol may increase the hypercalcemic activities of trichlormethiazide.


Doxercalciferol may increase the hypercalcemic activities of methyclothiazide.


ergocalciferol may increase the hypercalcemic activities of polythiazide.


toremifene may increase the hypercalcemic activities of chlorthalidone.


Calcifediol may increase the hypercalcemic activities of hydrochlorothiazide.


Doxercalciferol may increase the hypercalcemic activities of polythiazide.


dihydrotachysterol may increase the hypercalcemic activities of hydroflumethiazide.


Calcipotriol may increase the hypercalcemic activities of hydroflumethiazide.


Paricalcitol may increase the hypercalcemic activities of chlorothiazide.


Doxercalciferol may increase the hypercalcemic activities of indapamide.


Doxercalciferol may increase the hypercalcemic activities of QUINETHAZONE.


Calcifediol may increase the hypercalcemic activities of danazol.


Paricalcitol may increase the hypercalcemic activities of hydroflumethiazide.


Paricalcitol may increase the hypercalcemic activities of trichlormethiazide.


Calcipotriol may increase the hypercalcemic activities of chlorothiazide.


toremifene may increase the hypercalcemic activities of QUINETHAZONE.


toremifene may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


dihydrotachysterol may increase the hypercalcemic activities of QUINETHAZONE.


ergocalciferol may increase the hypercalcemic activities of QUINETHAZONE.


ergocalciferol may increase the hypercalcemic activities of hydroflumethiazide.


toremifene may increase the hypercalcemic activities of metolazone.


ergocalciferol may increase the hypercalcemic activities of indapamide.


Paricalcitol may increase the hypercalcemic activities of danazol.


ergocalciferol may increase the hypercalcemic activities of trichlormethiazide.


Paricalcitol may increase the hypercalcemic activities of methyclothiazide.


Calcipotriol may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


dihydrotachysterol may increase the hypercalcemic activities of hydrochlorothiazide.


toremifene may increase the hypercalcemic activities of chlorothiazide.


Paricalcitol may increase the hypercalcemic activities of chlorthalidone.


Calcipotriol may increase the hypercalcemic activities of methyclothiazide.


Calcipotriol may increase the hypercalcemic activities of polythiazide.


Calcipotriol may increase the hypercalcemic activities of QUINETHAZONE.


Calcifediol may increase the hypercalcemic activities of hydroflumethiazide.


toremifene may increase the hypercalcemic activities of trichlormethiazide.


Calcifediol may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


ergocalciferol may increase the hypercalcemic activities of chlorthalidone.


Calcifediol may increase the hypercalcemic activities of polythiazide.


Calcifediol may increase the hypercalcemic activities of QUINETHAZONE.


dihydrotachysterol may increase the hypercalcemic activities of danazol.


Doxercalciferol may increase the hypercalcemic activities of danazol.


dihydrotachysterol may increase the hypercalcemic activities of methyclothiazide.


Doxercalciferol may increase the hypercalcemic activities of hydrochlorothiazide.


ergocalciferol may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


dihydrotachysterol may increase the hypercalcemic activities of chlorthalidone.


dihydrotachysterol may increase the hypercalcemic activities of chlorothiazide.


Calcipotriol may increase the hypercalcemic activities of indapamide.


Calcifediol may increase the hypercalcemic activities of chlorothiazide.


Doxercalciferol may increase the hypercalcemic activities of hydroflumethiazide.


ergocalciferol may increase the hypercalcemic activities of danazol.


Calcifediol may increase the hypercalcemic activities of trichlormethiazide.


toremifene may increase the hypercalcemic activities of indapamide.


toremifene may increase the hypercalcemic activities of hydrochlorothiazide.


ergocalciferol may increase the hypercalcemic activities of hydrochlorothiazide.


Calcifediol may increase the hypercalcemic activities of chlorthalidone.


Paricalcitol may increase the hypercalcemic activities of hydrochlorothiazide.


Calcipotriol may increase the hypercalcemic activities of chlorthalidone.


dihydrotachysterol may increase the hypercalcemic activities of indapamide.


toremifene may increase the hypercalcemic activities of hydroflumethiazide.


Doxercalciferol may increase the hypercalcemic activities of metolazone.


Paricalcitol may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


Paricalcitol may increase the hypercalcemic activities of polythiazide.


Doxercalciferol may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


ergocalciferol may increase the hypercalcemic activities of methyclothiazide.


Calcipotriol may increase the hypercalcemic activities of metolazone.


Calcipotriol may increase the hypercalcemic activities of danazol.


dihydrotachysterol may increase the hypercalcemic activities of metolazone.


Paricalcitol may increase the hypercalcemic activities of metolazone.


Calcifediol may increase the hypercalcemic activities of methyclothiazide.


Calcifediol may increase the hypercalcemic activities of indapamide.


ergocalciferol may increase the hypercalcemic activities of metolazone.


Paricalcitol may increase the hypercalcemic activities of QUINETHAZONE.


Doxercalciferol may increase the hypercalcemic activities of chlorthalidone.


Doxercalciferol may increase the hypercalcemic activities of chlorothiazide.


Calcipotriol may increase the hypercalcemic activities of hydrochlorothiazide.


Calcifediol may increase the hypercalcemic activities of metolazone.


ergocalciferol may increase the hypercalcemic activities of chlorothiazide.


dihydrotachysterol may increase the hypercalcemic activities of BENDROFLUMETHIAZIDE.


dihydrotachysterol may increase the hypercalcemic activities of polythiazide.


Calcipotriol may increase the hypercalcemic activities of trichlormethiazide.


toremifene may increase the hypercalcemic activities of polythiazide.


Paricalcitol may increase the hypercalcemic activities of indapamide.


Doxercalciferol may increase the hypercalcemic activities of trichlormethiazide.


toremifene may increase the hypercalcemic activities of methyclothiazide.


Tapentadol may decrease the analgesic activities of Palonosetron.


Tramadol may decrease the analgesic activities of ondansetron.


Tapentadol may decrease the analgesic activities of tropisetron.


Tapentadol may decrease the analgesic activities of granisetron.


Tramadol may decrease the analgesic activities of granisetron.


Tramadol may decrease the analgesic activities of tropisetron.


Tramadol may decrease the analgesic activities of dolasetron.


DIHYDROCODEINE may decrease the analgesic activities of quinidine.


Tramadol may decrease the analgesic activities of Palonosetron.


Tapentadol may decrease the analgesic activities of dolasetron.


celecoxib may increase the antiplatelet activities of venlafaxine.


tirofiban may increase the antiplatelet activities of ILOPROST.


Cangrelor may increase the antiplatelet activities of ILOPROST.


Ifenprodil may increase the antiplatelet activities of ibudilast.


ibudilast may increase the antiplatelet activities of Limaprost.


Cangrelor may increase the antiplatelet activities of pentoxifylline.


celecoxib may increase the antiplatelet activities of citalopram.


Ifenprodil may increase the antiplatelet activities of ILOPROST.


trapidil may increase the antiplatelet activities of azelastine.


Ticagrelor may increase the antiplatelet activities of pentoxifylline.


Etoricoxib may increase the antiplatelet activities of Levomilnacipran.


dipyridamole may increase the antiplatelet activities of glucosamine.


Ifenprodil may increase the antiplatelet activities of alprostadil.


anagrelide may increase the antiplatelet activities of VITAMIN E.


Lumiracoxib may increase the antiplatelet activities of nefazodone.


sevoflurane may increase the antiplatelet activities of alprostadil.


ticlopidine may increase the antiplatelet activities of glucosamine.


trapidil may increase the antiplatelet activities of epoprostenol.


milrinone may increase the antiplatelet activities of epoprostenol.


dipyridamole may increase the antiplatelet activities of Treprostinil.


ethyl icosapentate may increase the antiplatelet activities of azelastine.


aspirin may increase the antiplatelet activities of paroxetine.


Ifenprodil may increase the antiplatelet activities of Treprostinil.


cilostazol may increase the antiplatelet activities of ILOPROST.


ethyl icosapentate may increase the antiplatelet activities of VITAMIN E.


Cangrelor may increase the antiplatelet activities of epoprostenol.


epinastine may increase the antiplatelet activities of VITAMIN E.


nabumetone may increase the antiplatelet activities of Levomilnacipran.


azelastine may increase the antiplatelet activities of milrinone.


alprostadil may increase the antiplatelet activities of epoprostenol.


clopidogrel may increase the antiplatelet activities of pentoxifylline.


sevoflurane may increase the antiplatelet activities of glucosamine.


anagrelide may increase the antiplatelet activities of glucosamine.


sevoflurane may increase the antiplatelet activities of milrinone.


nimesulide may increase the antiplatelet activities of sevoflurane.


alprostadil may increase the antiplatelet activities of ILOPROST.


anagrelide may increase the antiplatelet activities of pentoxifylline.


Ifenprodil may increase the antiplatelet activities of VITAMIN E.


Lumiracoxib may increase the antiplatelet activities of paroxetine.


milrinone may increase the antiplatelet activities of pentoxifylline.


alprostadil may increase the antiplatelet activities of epinastine.


nimesulide may increase the antiplatelet activities of glucosamine.


ethyl icosapentate may increase the antiplatelet activities of alprostadil.


etodolac may increase the antiplatelet activities of sertraline.


celecoxib may increase the antiplatelet activities of sertraline.


ibudilast may increase the antiplatelet activities of alprostadil.


ILOPROST may increase the antiplatelet activities of Treprostinil.


aspirin may increase the antiplatelet activities of Escitalopram.


aspirin may increase the antiplatelet activities of duloxetine.


resveratrol may increase the antiplatelet activities of epoprostenol.


aspirin may increase the antiplatelet activities of fluoxetine.


ethyl icosapentate may increase the antiplatelet activities of Treprostinil.


ethyl icosapentate may increase the antiplatelet activities of ILOPROST.


aspirin may increase the antiplatelet activities of Levomilnacipran.


Prasugrel may increase the antiplatelet activities of VITAMIN E.


resveratrol may increase the antiplatelet activities of ILOPROST.


resveratrol may increase the antiplatelet activities of milrinone.


Triflusal may increase the antiplatelet activities of pentoxifylline.


ethyl icosapentate may increase the antiplatelet activities of epoprostenol.


Cangrelor may increase the antiplatelet activities of Treprostinil.


etodolac may increase the antiplatelet activities of duloxetine.


aspirin may increase the antiplatelet activities of fluvoxamine.


Ifenprodil may increase the antiplatelet activities of nimesulide.


epinastine may increase the antiplatelet activities of Treprostinil.


cilostazol may increase the antiplatelet activities of VITAMIN E.


nimesulide may increase the antiplatelet activities of epinastine.


etodolac may increase the antiplatelet activities of fluvoxamine.


ibudilast may increase the antiplatelet activities of Treprostinil.


etodolac may increase the antiplatelet activities of fluoxetine.


cilostazol may increase the antiplatelet activities of Treprostinil.


alprostadil may increase the antiplatelet activities of glucosamine.


pentoxifylline may increase the antiplatelet activities of glucosamine.


azelastine may increase the antiplatelet activities of epoprostenol.


ethyl icosapentate may increase the antiplatelet activities of pentoxifylline.


epinastine may increase the antiplatelet activities of glucosamine.


Triflusal may increase the antiplatelet activities of glucosamine.


nabumetone may increase the antiplatelet activities of Escitalopram.


nabumetone may increase the antiplatelet activities of nefazodone.


sevoflurane may increase the antiplatelet activities of epinastine.


trapidil may increase the antiplatelet activities of ethyl icosapentate.


etodolac may increase the antiplatelet activities of venlafaxine.


epinastine may increase the antiplatelet activities of epoprostenol.


Ifenprodil may increase the antiplatelet activities of Limaprost.


resveratrol may increase the antiplatelet activities of epinastine.


pentoxifylline may increase the antiplatelet activities of Limaprost.


milrinone may increase the antiplatelet activities of ILOPROST.


resveratrol may increase the antiplatelet activities of sevoflurane.


ibudilast may increase the antiplatelet activities of glucosamine.


celecoxib may increase the antiplatelet activities of Levomilnacipran.


ethyl icosapentate may increase the antiplatelet activities of ibudilast.


resveratrol may increase the antiplatelet activities of Limaprost.


aspirin may increase the antiplatelet activities of VITAMIN E.


ticlopidine may increase the antiplatelet activities of epoprostenol.


nimesulide may increase the antiplatelet activities of pentoxifylline.


ethyl icosapentate may increase the antiplatelet activities of nimesulide.


epinastine may increase the antiplatelet activities of Limaprost.


ILOPROST may increase the antiplatelet activities of pentoxifylline.


tirofiban may increase the antiplatelet activities of VITAMIN E.


ticlopidine may increase the antiplatelet activities of pentoxifylline.


etodolac may increase the antiplatelet activities of citalopram.


Lumiracoxib may increase the antiplatelet activities of duloxetine.


trapidil may increase the antiplatelet activities of alprostadil.


aspirin may increase the antiplatelet activities of glucosamine.


celecoxib may increase the antiplatelet activities of Milnacipran.


Lumiracoxib may increase the antiplatelet activities of fluoxetine.


nimesulide may increase the antiplatelet activities of VITAMIN E.


nimesulide may increase the antiplatelet activities of Limaprost.


Lumiracoxib may increase the antiplatelet activities of Escitalopram.


nabumetone may increase the antiplatelet activities of sertraline.


ethyl icosapentate may increase the antiplatelet activities of Limaprost.


ibudilast may increase the antiplatelet activities of pentoxifylline.


Ifenprodil may increase the antiplatelet activities of resveratrol.


ibudilast may increase the antiplatelet activities of epinastine.


nabumetone may increase the antiplatelet activities of citalopram.


trapidil may increase the antiplatelet activities of ibudilast.


Prasugrel may increase the antiplatelet activities of glucosamine.


nabumetone may increase the antiplatelet activities of venlafaxine.


argatroban may increase the antiplatelet activities of glucosamine.


anagrelide may increase the antiplatelet activities of ILOPROST.


milrinone may increase the antiplatelet activities of Limaprost.


trapidil may increase the antiplatelet activities of glucosamine.


epoprostenol may increase the antiplatelet activities of VITAMIN E.


trapidil may increase the antiplatelet activities of milrinone.


nabumetone may increase the antiplatelet activities of Milnacipran.


Vorapaxar may increase the antiplatelet activities of ILOPROST.


aspirin may increase the antiplatelet activities of nefazodone.


trapidil may increase the antiplatelet activities of Ifenprodil.


ibudilast may increase the antiplatelet activities of resveratrol.


alprostadil may increase the antiplatelet activities of Treprostinil.


Ifenprodil may increase the antiplatelet activities of glucosamine.


trapidil may increase the antiplatelet activities of ILOPROST.


ticlopidine may increase the antiplatelet activities of Treprostinil.


aspirin may increase the antiplatelet activities of pentoxifylline.


Lumiracoxib may increase the antiplatelet activities of citalopram.


ibudilast may increase the antiplatelet activities of sevoflurane.


Ifenprodil may increase the antiplatelet activities of sevoflurane.


epoprostenol may increase the antiplatelet activities of Treprostinil.


azelastine may increase the antiplatelet activities of glucosamine.


nabumetone may increase the antiplatelet activities of duloxetine.


tirofiban may increase the antiplatelet activities of pentoxifylline.


resveratrol may increase the antiplatelet activities of glucosamine.


Ticagrelor may increase the antiplatelet activities of VITAMIN E.


Lumiracoxib may increase the antiplatelet activities of sertraline.


ibudilast may increase the antiplatelet activities of azelastine.


azelastine may increase the antiplatelet activities of ILOPROST.


Ifenprodil may increase the antiplatelet activities of milrinone.


Vorapaxar may increase the antiplatelet activities of VITAMIN E.


ethyl icosapentate may increase the antiplatelet activities of sevoflurane.


Ifenprodil may increase the antiplatelet activities of epoprostenol.


Lumiracoxib may increase the antiplatelet activities of venlafaxine.


Ifenprodil may increase the antiplatelet activities of ethyl icosapentate.


Etoricoxib may increase the antiplatelet activities of duloxetine.


trapidil may increase the antiplatelet activities of VITAMIN E.


trapidil may increase the antiplatelet activities of resveratrol.


ticlopidine may increase the antiplatelet activities of ILOPROST.


Vorapaxar may increase the antiplatelet activities of glucosamine.


epinastine may increase the antiplatelet activities of pentoxifylline.


nimesulide may increase the antiplatelet activities of milrinone.


tirofiban may increase the antiplatelet activities of epoprostenol.


ibudilast may increase the antiplatelet activities of epoprostenol.


Prasugrel may increase the antiplatelet activities of pentoxifylline.


epinastine may increase the antiplatelet activities of ILOPROST.


azelastine may increase the antiplatelet activities of VITAMIN E.


Triflusal may increase the antiplatelet activities of Treprostinil.


argatroban may increase the antiplatelet activities of pentoxifylline.


ibudilast may increase the antiplatelet activities of ILOPROST.


trapidil may increase the antiplatelet activities of Limaprost.


trapidil may increase the antiplatelet activities of pentoxifylline.


Cangrelor may increase the antiplatelet activities of glucosamine.


epoprostenol may increase the antiplatelet activities of pentoxifylline.


epoprostenol may increase the antiplatelet activities of glucosamine.


Lumiracoxib may increase the antiplatelet activities of Levomilnacipran.


dipyridamole may increase the antiplatelet activities of pentoxifylline.


epinastine may increase the antiplatelet activities of milrinone.


trapidil may increase the antiplatelet activities of Treprostinil.


Vorapaxar may increase the antiplatelet activities of epoprostenol.


sevoflurane may increase the antiplatelet activities of Treprostinil.


Prasugrel may increase the antiplatelet activities of epoprostenol.


trapidil may increase the antiplatelet activities of sevoflurane.


ibudilast may increase the antiplatelet activities of milrinone.


ethyl icosapentate may increase the antiplatelet activities of milrinone.


Ifenprodil may increase the antiplatelet activities of pentoxifylline.


Lumiracoxib may increase the antiplatelet activities of Milnacipran.


aspirin may increase the antiplatelet activities of sertraline.


Triflusal may increase the antiplatelet activities of VITAMIN E.


alprostadil may increase the antiplatelet activities of milrinone.


alprostadil may increase the antiplatelet activities of VITAMIN E.


clopidogrel may increase the antiplatelet activities of epoprostenol.


sevoflurane may increase the antiplatelet activities of pentoxifylline.


Etoricoxib may increase the antiplatelet activities of Escitalopram.


azelastine may increase the antiplatelet activities of pentoxifylline.


ethyl icosapentate may increase the antiplatelet activities of glucosamine.


etodolac may increase the antiplatelet activities of nefazodone.


resveratrol may increase the antiplatelet activities of pentoxifylline.


anagrelide may increase the antiplatelet activities of epoprostenol.


sevoflurane may increase the antiplatelet activities of VITAMIN E.


tirofiban may increase the antiplatelet activities of glucosamine.


Etoricoxib may increase the antiplatelet activities of venlafaxine.


aspirin may increase the antiplatelet activities of venlafaxine.


etodolac may increase the antiplatelet activities of Escitalopram.


tirofiban may increase the antiplatelet activities of Treprostinil.


etodolac may increase the antiplatelet activities of Levomilnacipran.


cilostazol may increase the antiplatelet activities of pentoxifylline.


Prasugrel may increase the antiplatelet activities of ILOPROST.


ibudilast may increase the antiplatelet activities of nimesulide.


azelastine may increase the antiplatelet activities of epinastine.


Ticagrelor may increase the antiplatelet activities of aspirin.


Vorapaxar may increase the antiplatelet activities of Treprostinil.


pentoxifylline may increase the antiplatelet activities of VITAMIN E.


dipyridamole may increase the antiplatelet activities of VITAMIN E.


sevoflurane may increase the antiplatelet activities of Limaprost.


clopidogrel may increase the antiplatelet activities of VITAMIN E.


Etoricoxib may increase the antiplatelet activities of citalopram.


Triflusal may increase the antiplatelet activities of ILOPROST.


ILOPROST may increase the antiplatelet activities of glucosamine.


Triflusal may increase the antiplatelet activities of epoprostenol.


Etoricoxib may increase the antiplatelet activities of sertraline.


argatroban may increase the antiplatelet activities of epoprostenol.


celecoxib may increase the antiplatelet activities of Escitalopram.


milrinone may increase the antiplatelet activities of glucosamine.


nabumetone may increase the antiplatelet activities of paroxetine.


trapidil may increase the antiplatelet activities of epinastine.


argatroban may increase the antiplatelet activities of Treprostinil.


argatroban may increase the antiplatelet activities of ILOPROST.


nimesulide may increase the antiplatelet activities of ILOPROST.


milrinone may increase the antiplatelet activities of Treprostinil.


milrinone may increase the antiplatelet activities of VITAMIN E.


cilostazol may increase the antiplatelet activities of epoprostenol.


Vorapaxar may increase the antiplatelet activities of pentoxifylline.


etodolac may increase the antiplatelet activities of Milnacipran.


celecoxib may increase the antiplatelet activities of paroxetine.


celecoxib may increase the antiplatelet activities of duloxetine.


clopidogrel may increase the antiplatelet activities of glucosamine.


clopidogrel may increase the antiplatelet activities of Treprostinil.


celecoxib may increase the antiplatelet activities of fluoxetine.


etodolac may increase the antiplatelet activities of paroxetine.


resveratrol may increase the antiplatelet activities of VITAMIN E.


ethyl icosapentate may increase the antiplatelet activities of epinastine.


cilostazol may increase the antiplatelet activities of glucosamine.


ticlopidine may increase the antiplatelet activities of VITAMIN E.


Ifenprodil may increase the antiplatelet activities of epinastine.


ibudilast may increase the antiplatelet activities of VITAMIN E.


ILOPROST may increase the antiplatelet activities of VITAMIN E.


trapidil may increase the antiplatelet activities of nimesulide.


alprostadil may increase the antiplatelet activities of Limaprost.


Prasugrel may increase the antiplatelet activities of Treprostinil.


clopidogrel may increase the antiplatelet activities of ILOPROST.


nabumetone may increase the antiplatelet activities of fluoxetine.


Etoricoxib may increase the antiplatelet activities of Milnacipran.


Ticagrelor may increase the antiplatelet activities of glucosamine.


alprostadil may increase the antiplatelet activities of pentoxifylline.


aspirin may increase the antiplatelet activities of citalopram.


Cangrelor may increase the antiplatelet activities of VITAMIN E.


azelastine may increase the antiplatelet activities of Limaprost.


Ibrutinib may increase the antiplatelet activities of VITAMIN E.


aspirin may increase the antiplatelet activities of Milnacipran.


ethyl icosapentate may increase the antiplatelet activities of resveratrol.


Ifenprodil may increase the antiplatelet activities of azelastine.


nimesulide may increase the antiplatelet activities of epoprostenol.


celecoxib may increase the antiplatelet activities of fluvoxamine.


digoxin may increase the bradycardic activities of rivastigmine.


nadolol may increase the bradycardic activities of Crizotinib.


Octreotide may increase the bradycardic activities of donepezil.


pyridostigmine may increase the bradycardic activities of atenolol.


carvedilol may increase the bradycardic activities of Fingolimod.


clonidine may increase the bradycardic activities of Lanreotide.


nadolol may increase the bradycardic activities of Fingolimod.


labetalol may increase the bradycardic activities of ouabain.


alprenolol may increase the bradycardic activities of midodrine.


penbutolol may increase the bradycardic activities of Pasireotide.


BISOPROLOL may increase the bradycardic activities of Fingolimod.


nadolol may increase the bradycardic activities of ceritinib.


dipyridamole may increase the bradycardic activities of Bevantolol.


dipyridamole may increase the bradycardic activities of alprenolol.


dipyridamole may increase the bradycardic activities of practolol.


Dronedarone may increase the bradycardic activities of BUPRANOLOL.


succinylcholine may increase the bradycardic activities of Tapentadol.


VERAPAMIL may increase the bradycardic activities of amiodarone.


memantine may increase the bradycardic activities of BISOPROLOL.


memantine may increase the bradycardic activities of labetalol.


physostigmine may increase the bradycardic activities of LEVOBUNOLOL.


amiodarone may increase the bradycardic activities of propranolol.


disopyramide may increase the bradycardic activities of propranolol.


Dronedarone may increase the bradycardic activities of timolol.


timolol may increase the bradycardic activities of acetyldigitoxin.


amiodarone may increase the bradycardic activities of labetalol.


ALFENTANIL may increase the bradycardic activities of carvedilol.


tubocurarine may increase the bradycardic activities of ESMOLOL.


malathion may increase the bradycardic activities of penbutolol.


mefloquine may increase the bradycardic activities of celiprolol.


galanthamine may increase the bradycardic activities of oxprenolol.


donepezil may increase the bradycardic activities of BOPINDOLOL.


methyldopa may increase the bradycardic activities of Dronedarone.


clonidine may increase the bradycardic activities of Ivabradine.


BENDROFLUMETHIAZIDE may increase the bradycardic activities of Pasireotide.


dipyridamole may increase the bradycardic activities of nadolol.


atenolol may increase the bradycardic activities of Pasireotide.


practolol may increase the bradycardic activities of midodrine.


DEXMEDETOMIDINE may increase the bradycardic activities of Fingolimod.


propafenone may increase the bradycardic activities of Lanreotide.


Octreotide may increase the bradycardic activities of timolol.


donepezil may increase the bradycardic activities of propranolol.


Echothiophate may increase the bradycardic activities of Nebivolol.


metoprolol may increase the bradycardic activities of Ivabradine.


digoxin may increase the bradycardic activities of sotalol.


Metipranolol may increase the bradycardic activities of ouabain.


Metipranolol may increase the bradycardic activities of Ivabradine.


edrophonium may increase the bradycardic activities of metoprolol.


clonidine may increase the bradycardic activities of propafenone.


amiodarone may increase the bradycardic activities of Bevantolol.


Ruxolitinib may increase the bradycardic activities of Lanreotide.


amiodarone may increase the bradycardic activities of practolol.


Tofacitinib may increase the bradycardic activities of Octreotide.


NEOSTIGMINE may increase the bradycardic activities of oxprenolol.


Octreotide may increase the bradycardic activities of BISOPROLOL.


ALFENTANIL may increase the bradycardic activities of Arotinolol.


labetalol may increase the bradycardic activities of deslanoside.


Tofacitinib may increase the bradycardic activities of donepezil.


BENDROFLUMETHIAZIDE may increase the bradycardic activities of rivastigmine.


celiprolol may increase the bradycardic activities of digitoxin.


amiodarone may increase the bradycardic activities of acebutolol.


Dronedarone may increase the bradycardic activities of betaxolol.


DEXMEDETOMIDINE may increase the bradycardic activities of rivastigmine.


NEOSTIGMINE may increase the bradycardic activities of sotalol.


Ruxolitinib may increase the bradycardic activities of galanthamine.


succinylcholine may increase the bradycardic activities of DEZOCINE.


donepezil may increase the bradycardic activities of BUPRANOLOL.


decamethonium may increase the bradycardic activities of Nebivolol.


SUFENTANIL may increase the bradycardic activities of Fingolimod.


Ruxolitinib may increase the bradycardic activities of Crizotinib.


metoclopramide may increase the bradycardic activities of atenolol.


Dronedarone may increase the bradycardic activities of BISOPROLOL.


edrophonium may increase the bradycardic activities of betaxolol.


Regorafenib may increase the bradycardic activities of BOPINDOLOL.


donepezil may increase the bradycardic activities of betaxolol.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of BISOPROLOL.


metoprolol may increase the bradycardic activities of Fingolimod.


Regorafenib may increase the bradycardic activities of BUPRANOLOL.


Demecarium may increase the bradycardic activities of nadolol.


CARTEOLOL may increase the bradycardic activities of ceritinib.


CARTEOLOL may increase the bradycardic activities of Lanreotide.


acebutolol may increase the bradycardic activities of Pasireotide.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of sotalol.


carvedilol may increase the bradycardic activities of rivastigmine.


Bretylium may increase the bradycardic activities of propranolol.


Arotinolol may increase the bradycardic activities of Fingolimod.


Bretylium may increase the bradycardic activities of clonidine.


betaxolol may increase the bradycardic activities of Lanreotide.


LEVOBUNOLOL may increase the bradycardic activities of rivastigmine.


Regorafenib may increase the bradycardic activities of alprenolol.


Ruxolitinib may increase the bradycardic activities of tizanidine.


nadolol may increase the bradycardic activities of digitoxin.


Isoflurophate may increase the bradycardic activities of Arotinolol.


Octreotide may increase the bradycardic activities of galanthamine.


BOPINDOLOL may increase the bradycardic activities of midodrine.


NEOSTIGMINE may increase the bradycardic activities of Metipranolol.


amiodarone may increase the bradycardic activities of oxprenolol.


BOPINDOLOL may increase the bradycardic activities of ouabain.


NEOSTIGMINE may increase the bradycardic activities of penbutolol.


tubocurarine may increase the bradycardic activities of atenolol.


Arotinolol may increase the bradycardic activities of rivastigmine.


Dronedarone may increase the bradycardic activities of penbutolol.


diltiazem may increase the bradycardic activities of amiodarone.


Dronedarone may increase the bradycardic activities of Metipranolol.


amiodarone may increase the bradycardic activities of betaxolol.


disopyramide may increase the bradycardic activities of betaxolol.


ESMOLOL may increase the bradycardic activities of ceritinib.


practolol may increase the bradycardic activities of Fingolimod.


Bretylium may increase the bradycardic activities of propafenone.


edrophonium may increase the bradycardic activities of LEVOBUNOLOL.


Echothiophate may increase the bradycardic activities of BOPINDOLOL.


BISOPROLOL may increase the bradycardic activities of deslanoside.


metoclopramide may increase the bradycardic activities of Nebivolol.


pyridostigmine may increase the bradycardic activities of CARTEOLOL.


memantine may increase the bradycardic activities of timolol.


Ruxolitinib may increase the bradycardic activities of labetalol.


timolol may increase the bradycardic activities of SUFENTANIL.


disopyramide may increase the bradycardic activities of BISOPROLOL.


LEVOBUNOLOL may increase the bradycardic activities of deslanoside.


Demecarium may increase the bradycardic activities of ESMOLOL.


Ruxolitinib may increase the bradycardic activities of nadolol.


mefloquine may increase the bradycardic activities of Bevantolol.


Bretylium may increase the bradycardic activities of timolol.


memantine may increase the bradycardic activities of propranolol.


BOPINDOLOL may increase the bradycardic activities of acetyldigitoxin.


Bretylium may increase the bradycardic activities of tizanidine.


BENDROFLUMETHIAZIDE may increase the bradycardic activities of Dronedarone.


Ruxolitinib may increase the bradycardic activities of Dronedarone.


pyridostigmine may increase the bradycardic activities of oxprenolol.


carvedilol may increase the bradycardic activities of Pasireotide.


tizanidine may increase the bradycardic activities of donepezil.


LEVOBUNOLOL may increase the bradycardic activities of midodrine.


BOPINDOLOL may increase the bradycardic activities of deslanoside.


galanthamine may increase the bradycardic activities of metoprolol.


Regorafenib may increase the bradycardic activities of diltiazem.


Regorafenib may increase the bradycardic activities of metoprolol.


pyridostigmine may increase the bradycardic activities of BUPRANOLOL.


labetalol may increase the bradycardic activities of Lanreotide.


galanthamine may increase the bradycardic activities of Pasireotide.


ALFENTANIL may increase the bradycardic activities of alprenolol.


donepezil may increase the bradycardic activities of GUANFACINE.


ambenonium may increase the bradycardic activities of labetalol.


metoprolol may increase the bradycardic activities of SUFENTANIL.


metoprolol may increase the bradycardic activities of ouabain.


disopyramide may increase the bradycardic activities of Metipranolol.


Tofacitinib may increase the bradycardic activities of diltiazem.


Tofacitinib may increase the bradycardic activities of BENDROFLUMETHIAZIDE.


ambenonium may increase the bradycardic activities of acebutolol.


Metipranolol may increase the bradycardic activities of deslanoside.


Demecarium may increase the bradycardic activities of labetalol.


timolol may increase the bradycardic activities of Fingolimod.


galanthamine may increase the bradycardic activities of Nebivolol.


GUANFACINE may increase the bradycardic activities of Ivabradine.


Ruxolitinib may increase the bradycardic activities of clonidine.


succinylcholine may increase the bradycardic activities of DIHYDROCODEINE.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of metoprolol.


succinylcholine may increase the bradycardic activities of Ketobemidone.


Bretylium may increase the bradycardic activities of nadolol.


Metipranolol may increase the bradycardic activities of digitoxin.


edrophonium may increase the bradycardic activities of BUPRANOLOL.


Bretylium may increase the bradycardic activities of ESMOLOL.


donepezil may increase the bradycardic activities of Fingolimod.


digitoxin may increase the bradycardic activities of midodrine.


Octreotide may increase the bradycardic activities of ceritinib.


BOPINDOLOL may increase the bradycardic activities of digitoxin.


ambenonium may increase the bradycardic activities of ESMOLOL.


physostigmine may increase the bradycardic activities of Bevantolol.


penbutolol may increase the bradycardic activities of acetyldigitoxin.


dipyridamole may increase the bradycardic activities of BUPRANOLOL.


Isoflurophate may increase the bradycardic activities of betaxolol.


Ruxolitinib may increase the bradycardic activities of propranolol.


NEOSTIGMINE may increase the bradycardic activities of labetalol.


donepezil may increase the bradycardic activities of rivastigmine.


Pasireotide may increase the bradycardic activities of ceritinib.


practolol may increase the bradycardic activities of ouabain.


galanthamine may increase the bradycardic activities of GUANFACINE.


clonidine may increase the bradycardic activities of galanthamine.


rivastigmine may increase the bradycardic activities of Dronedarone.


BISOPROLOL may increase the bradycardic activities of SUFENTANIL.


pyridostigmine may increase the bradycardic activities of ESMOLOL.


edrophonium may increase the bradycardic activities of Metipranolol.


succinylcholine may increase the bradycardic activities of hydromorphone.


betaxolol may increase the bradycardic activities of midodrine.


mefloquine may increase the bradycardic activities of oxprenolol.


BENDROFLUMETHIAZIDE may increase the bradycardic activities of Fingolimod.


physostigmine may increase the bradycardic activities of alprenolol.


Bretylium may increase the bradycardic activities of labetalol.


amiodarone may increase the bradycardic activities of Lanreotide.


mefloquine may increase the bradycardic activities of CARTEOLOL.


Dronedarone may increase the bradycardic activities of carvedilol.


penbutolol may increase the bradycardic activities of Ivabradine.


ALFENTANIL may increase the bradycardic activities of nadolol.


ambenonium may increase the bradycardic activities of oxprenolol.


Tofacitinib may increase the bradycardic activities of sotalol.


edrophonium may increase the bradycardic activities of celiprolol.


Tofacitinib may increase the bradycardic activities of atenolol.


malathion may increase the bradycardic activities of oxprenolol.


atenolol may increase the bradycardic activities of Ivabradine.


Octreotide may increase the bradycardic activities of atenolol.


betaxolol may increase the bradycardic activities of Pasireotide.


Demecarium may increase the bradycardic activities of CARTEOLOL.


succinylcholine may increase the bradycardic activities of methadone.


pyridostigmine may increase the bradycardic activities of acebutolol.


donepezil may increase the bradycardic activities of practolol.


alprenolol may increase the bradycardic activities of acetyldigitoxin.


acebutolol may increase the bradycardic activities of ceritinib.


SUFENTANIL may increase the bradycardic activities of Ivabradine.


acebutolol may increase the bradycardic activities of Crizotinib.


mefloquine may increase the bradycardic activities of LEVOBUNOLOL.


Isoflurophate may increase the bradycardic activities of timolol.


acebutolol may increase the bradycardic activities of Fingolimod.


tubocurarine may increase the bradycardic activities of acebutolol.


carvedilol may increase the bradycardic activities of acetyldigitoxin.


galanthamine may increase the bradycardic activities of carvedilol.


Ruxolitinib may increase the bradycardic activities of diltiazem.


Dronedarone may increase the bradycardic activities of Arotinolol.


physostigmine may increase the bradycardic activities of nadolol.


memantine may increase the bradycardic activities of oxprenolol.


betaxolol may increase the bradycardic activities of deslanoside.


atenolol may increase the bradycardic activities of rivastigmine.


malathion may increase the bradycardic activities of Arotinolol.


donepezil may increase the bradycardic activities of sotalol.


malathion may increase the bradycardic activities of Bevantolol.


labetalol may increase the bradycardic activities of Crizotinib.


malathion may increase the bradycardic activities of practolol.


amiodarone may increase the bradycardic activities of BOPINDOLOL.


Arotinolol may increase the bradycardic activities of deslanoside.


sotalol may increase the bradycardic activities of Ivabradine.


BENDROFLUMETHIAZIDE may increase the bradycardic activities of galanthamine.


sotalol may increase the bradycardic activities of ouabain.


dipyridamole may increase the bradycardic activities of Nebivolol.


Ruxolitinib may increase the bradycardic activities of BENDROFLUMETHIAZIDE.


methyldopa may increase the bradycardic activities of amiodarone.


alprenolol may increase the bradycardic activities of rivastigmine.


timolol may increase the bradycardic activities of ouabain.


labetalol may increase the bradycardic activities of acetyldigitoxin.


diltiazem may increase the bradycardic activities of Fingolimod.


ALFENTANIL may increase the bradycardic activities of labetalol.


clonidine may increase the bradycardic activities of Pasireotide.


metoclopramide may increase the bradycardic activities of alprenolol.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of acebutolol.


timolol may increase the bradycardic activities of Ivabradine.


memantine may increase the bradycardic activities of ESMOLOL.


succinylcholine may increase the bradycardic activities of SUFENTANIL.


Dronedarone may increase the bradycardic activities of celiprolol.


Ruxolitinib may increase the bradycardic activities of Pasireotide.


dipyridamole may increase the bradycardic activities of acebutolol.


tizanidine may increase the bradycardic activities of Pasireotide.


Isoflurophate may increase the bradycardic activities of propranolol.


disopyramide may increase the bradycardic activities of Arotinolol.


Bevantolol may increase the bradycardic activities of digitoxin.


SUFENTANIL may increase the bradycardic activities of Metipranolol.


oxprenolol may increase the bradycardic activities of ouabain.


decamethonium may increase the bradycardic activities of BISOPROLOL.


decamethonium may increase the bradycardic activities of labetalol.


galanthamine may increase the bradycardic activities of penbutolol.


BENDROFLUMETHIAZIDE may increase the bradycardic activities of Lanreotide.


pyridostigmine may increase the bradycardic activities of sotalol.


succinylcholine may increase the bradycardic activities of butorphanol.


ALFENTANIL may increase the bradycardic activities of ESMOLOL.


digoxin may increase the bradycardic activities of nadolol.


mefloquine may increase the bradycardic activities of ESMOLOL.


DEXMEDETOMIDINE may increase the bradycardic activities of Ivabradine.


ESMOLOL may increase the bradycardic activities of Pasireotide.


NEOSTIGMINE may increase the bradycardic activities of propranolol.


Ruxolitinib may increase the bradycardic activities of sotalol.


malathion may increase the bradycardic activities of nadolol.


Arotinolol may increase the bradycardic activities of digoxin.


SUFENTANIL may increase the bradycardic activities of Pasireotide.


digoxin may increase the bradycardic activities of SUFENTANIL.


CARTEOLOL may increase the bradycardic activities of Pasireotide.


Demecarium may increase the bradycardic activities of betaxolol.


donepezil may increase the bradycardic activities of Nebivolol.


decamethonium may increase the bradycardic activities of Metipranolol.


donepezil may increase the bradycardic activities of acebutolol.


decamethonium may increase the bradycardic activities of LEVOBUNOLOL.


Bretylium may increase the bradycardic activities of Nebivolol.


Bretylium may increase the bradycardic activities of GUANFACINE.


disopyramide may increase the bradycardic activities of celiprolol.


acebutolol may increase the bradycardic activities of digitoxin.


Echothiophate may increase the bradycardic activities of acebutolol.


pyridostigmine may increase the bradycardic activities of BOPINDOLOL.


dipyridamole may increase the bradycardic activities of oxprenolol.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of penbutolol.


diltiazem may increase the bradycardic activities of Ivabradine.


labetalol may increase the bradycardic activities of SUFENTANIL.


Bretylium may increase the bradycardic activities of digoxin.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of Bevantolol.


Dronedarone may increase the bradycardic activities of alprenolol.


pyridostigmine may increase the bradycardic activities of labetalol.


penbutolol may increase the bradycardic activities of ouabain.


Isoflurophate may increase the bradycardic activities of BOPINDOLOL.


Nebivolol may increase the bradycardic activities of ceritinib.


Tofacitinib may increase the bradycardic activities of propranolol.


CARTEOLOL may increase the bradycardic activities of midodrine.


Tofacitinib may increase the bradycardic activities of clonidine.


Metipranolol may increase the bradycardic activities of midodrine.


celiprolol may increase the bradycardic activities of acetyldigitoxin.


ESMOLOL may increase the bradycardic activities of midodrine.


labetalol may increase the bradycardic activities of Ivabradine.


SUFENTANIL may increase the bradycardic activities of rivastigmine.


succinylcholine may increase the bradycardic activities of propoxyphene.


tubocurarine may increase the bradycardic activities of Arotinolol.


deslanoside may increase the bradycardic activities of midodrine.


Isoflurophate may increase the bradycardic activities of nadolol.


ambenonium may increase the bradycardic activities of CARTEOLOL.


Echothiophate may increase the bradycardic activities of ESMOLOL.


dipyridamole may increase the bradycardic activities of timolol.


BISOPROLOL may increase the bradycardic activities of Pasireotide.


Bevantolol may increase the bradycardic activities of ouabain.


Echothiophate may increase the bradycardic activities of BUPRANOLOL.


Ruxolitinib may increase the bradycardic activities of metoprolol.


betaxolol may increase the bradycardic activities of ouabain.


succinylcholine may increase the bradycardic activities of morphine.


physostigmine may increase the bradycardic activities of Nebivolol.


Tofacitinib may increase the bradycardic activities of Crizotinib.


timolol may increase the bradycardic activities of Pasireotide.


decamethonium may increase the bradycardic activities of metoprolol.


Metipranolol may increase the bradycardic activities of rivastigmine.


metoprolol may increase the bradycardic activities of Pasireotide.


tizanidine may increase the bradycardic activities of ceritinib.


Demecarium may increase the bradycardic activities of oxprenolol.


dipyridamole may increase the bradycardic activities of betaxolol.


mefloquine may increase the bradycardic activities of Arotinolol.


metoprolol may increase the bradycardic activities of ceritinib.


Ruxolitinib may increase the bradycardic activities of Nebivolol.


BOPINDOLOL may increase the bradycardic activities of Fingolimod.


ALFENTANIL may increase the bradycardic activities of CARTEOLOL.


NEOSTIGMINE may increase the bradycardic activities of Arotinolol.


Daclatasvir may increase the bradycardic activities of amiodarone.


acetyldigitoxin may increase the bradycardic activities of midodrine.


disopyramide may increase the bradycardic activities of alprenolol.


Echothiophate may increase the bradycardic activities of BISOPROLOL.


ouabain may increase the bradycardic activities of midodrine.


galanthamine may increase the bradycardic activities of betaxolol.


edrophonium may increase the bradycardic activities of oxprenolol.


diltiazem may increase the bradycardic activities of Pasireotide.


succinylcholine may increase the bradycardic activities of HYDROCODONE.


Tofacitinib may increase the bradycardic activities of timolol.


edrophonium may increase the bradycardic activities of CARTEOLOL.


tubocurarine may increase the bradycardic activities of practolol.


Bevantolol may increase the bradycardic activities of acetyldigitoxin.


tubocurarine may increase the bradycardic activities of penbutolol.


memantine may increase the bradycardic activities of carvedilol.


galanthamine may increase the bradycardic activities of tizanidine.


Ruxolitinib may increase the bradycardic activities of propafenone.


methyldopa may increase the bradycardic activities of ceritinib.


oxprenolol may increase the bradycardic activities of deslanoside.


DEXMEDETOMIDINE may increase the bradycardic activities of Crizotinib.


ESMOLOL may increase the bradycardic activities of Ivabradine.


methyldopa may increase the bradycardic activities of Pasireotide.


NEOSTIGMINE may increase the bradycardic activities of carvedilol.


physostigmine may increase the bradycardic activities of atenolol.


timolol may increase the bradycardic activities of rivastigmine.


edrophonium may increase the bradycardic activities of penbutolol.


malathion may increase the bradycardic activities of LEVOBUNOLOL.


memantine may increase the bradycardic activities of Bevantolol.


NEOSTIGMINE may increase the bradycardic activities of CARTEOLOL.


sotalol may increase the bradycardic activities of rivastigmine.


Dronedarone may increase the bradycardic activities of oxprenolol.


disopyramide may increase the bradycardic activities of Bevantolol.


malathion may increase the bradycardic activities of celiprolol.


ALFENTANIL may increase the bradycardic activities of LEVOBUNOLOL.


Bevantolol may increase the bradycardic activities of Fingolimod.


pyridostigmine may increase the bradycardic activities of carvedilol.


methyldopa may increase the bradycardic activities of Ivabradine.


ambenonium may increase the bradycardic activities of celiprolol.


Octreotide may increase the bradycardic activities of DEXMEDETOMIDINE.


Octreotide may increase the bradycardic activities of penbutolol.


Tofacitinib may increase the bradycardic activities of betaxolol.


ambenonium may increase the bradycardic activities of nadolol.


Octreotide may increase the bradycardic activities of Metipranolol.


labetalol may increase the bradycardic activities of Pasireotide.


malathion may increase the bradycardic activities of BUPRANOLOL.


malathion may increase the bradycardic activities of BOPINDOLOL.


metoclopramide may increase the bradycardic activities of CARTEOLOL.


Metipranolol may increase the bradycardic activities of Fingolimod.


memantine may increase the bradycardic activities of nadolol.


digoxin may increase the bradycardic activities of galanthamine.


disopyramide may increase the bradycardic activities of timolol.


Tofacitinib may increase the bradycardic activities of BISOPROLOL.


donepezil may increase the bradycardic activities of LEVOBUNOLOL.


edrophonium may increase the bradycardic activities of labetalol.


physostigmine may increase the bradycardic activities of Metipranolol.


donepezil may increase the bradycardic activities of BISOPROLOL.


dipyridamole may increase the bradycardic activities of LEVOBUNOLOL.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of Metipranolol.


Octreotide may increase the bradycardic activities of diltiazem.


Dronedarone may increase the bradycardic activities of labetalol.


dipyridamole may increase the bradycardic activities of Metipranolol.


sotalol may increase the bradycardic activities of midodrine.


donepezil may increase the bradycardic activities of methyldopa.


succinylcholine may increase the bradycardic activities of ALFENTANIL.


malathion may increase the bradycardic activities of alprenolol.


physostigmine may increase the bradycardic activities of BISOPROLOL.


Demecarium may increase the bradycardic activities of BOPINDOLOL.


Demecarium may increase the bradycardic activities of BUPRANOLOL.


galanthamine may increase the bradycardic activities of Lanreotide.


succinylcholine may increase the bradycardic activities of pentazocine.


pyridostigmine may increase the bradycardic activities of Bevantolol.


LEVOBUNOLOL may increase the bradycardic activities of Crizotinib.


ESMOLOL may increase the bradycardic activities of Lanreotide.


metoclopramide may increase the bradycardic activities of acebutolol.


Bretylium may increase the bradycardic activities of amiodarone.


disopyramide may increase the bradycardic activities of nadolol.


metoclopramide may increase the bradycardic activities of Metipranolol.


Tofacitinib may increase the bradycardic activities of penbutolol.


pyridostigmine may increase the bradycardic activities of timolol.


metoclopramide may increase the bradycardic activities of LEVOBUNOLOL.


Tofacitinib may increase the bradycardic activities of Metipranolol.


Octreotide may increase the bradycardic activities of SUFENTANIL.


betaxolol may increase the bradycardic activities of Fingolimod.


Dronedarone may increase the bradycardic activities of ESMOLOL.


malathion may increase the bradycardic activities of atenolol.


disopyramide may increase the bradycardic activities of carvedilol.


Tofacitinib may increase the bradycardic activities of Pasireotide.


edrophonium may increase the bradycardic activities of ESMOLOL.


Demecarium may increase the bradycardic activities of Metipranolol.


donepezil may increase the bradycardic activities of alprenolol.


metoclopramide may increase the bradycardic activities of penbutolol.


betaxolol may increase the bradycardic activities of Crizotinib.


Octreotide may increase the bradycardic activities of LEVOBUNOLOL.


memantine may increase the bradycardic activities of metoprolol.


Ruxolitinib may increase the bradycardic activities of betaxolol.


Isoflurophate may increase the bradycardic activities of atenolol.


metoprolol may increase the bradycardic activities of Crizotinib.


practolol may increase the bradycardic activities of rivastigmine.


rivastigmine may increase the bradycardic activities of propafenone.


Demecarium may increase the bradycardic activities of LEVOBUNOLOL.


Echothiophate may increase the bradycardic activities of celiprolol.


metoclopramide may increase the bradycardic activities of ESMOLOL.


BUPRANOLOL may increase the bradycardic activities of digoxin.


Octreotide may increase the bradycardic activities of carvedilol.


DEXMEDETOMIDINE may increase the bradycardic activities of ceritinib.


metoclopramide may increase the bradycardic activities of oxprenolol.


methyldopa may increase the bradycardic activities of Crizotinib.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of alprenolol.


methyldopa may increase the bradycardic activities of Fingolimod.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of Nebivolol.


atenolol may increase the bradycardic activities of SUFENTANIL.


physostigmine may increase the bradycardic activities of Arotinolol.


digoxin may increase the bradycardic activities of GUANFACINE.


donepezil may increase the bradycardic activities of metoprolol.


donepezil may increase the bradycardic activities of Metipranolol.


Bevantolol may increase the bradycardic activities of rivastigmine.


Dronedarone may increase the bradycardic activities of nadolol.


Isoflurophate may increase the bradycardic activities of Nebivolol.


Isoflurophate may increase the bradycardic activities of CARTEOLOL.


pyridostigmine may increase the bradycardic activities of Arotinolol.


Fingolimod may increase the bradycardic activities of Ivabradine.


disopyramide may increase the bradycardic activities of ESMOLOL.


SUFENTANIL may increase the bradycardic activities of alprenolol.


Demecarium may increase the bradycardic activities of BISOPROLOL.


metoprolol may increase the bradycardic activities of digitoxin.


CARTEOLOL may increase the bradycardic activities of Ivabradine.


tubocurarine may increase the bradycardic activities of carvedilol.


labetalol may increase the bradycardic activities of Fingolimod.


Regorafenib may increase the bradycardic activities of nadolol.


dipyridamole may increase the bradycardic activities of atenolol.


Lanreotide may increase the bradycardic activities of ceritinib.


ESMOLOL may increase the bradycardic activities of digoxin.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of LEVOBUNOLOL.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of BOPINDOLOL.


BISOPROLOL may increase the bradycardic activities of Ivabradine.


Arotinolol may increase the bradycardic activities of acetyldigitoxin.


Bretylium may increase the bradycardic activities of diltiazem.


NEOSTIGMINE may increase the bradycardic activities of practolol.


Bretylium may increase the bradycardic activities of metoprolol.


NEOSTIGMINE may increase the bradycardic activities of Bevantolol.


ESMOLOL may increase the bradycardic activities of acetyldigitoxin.


Echothiophate may increase the bradycardic activities of timolol.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of practolol.


Ruxolitinib may increase the bradycardic activities of GUANFACINE.


galanthamine may increase the bradycardic activities of CARTEOLOL.


decamethonium may increase the bradycardic activities of oxprenolol.


betaxolol may increase the bradycardic activities of rivastigmine.


edrophonium may increase the bradycardic activities of Arotinolol.


disopyramide may increase the bradycardic activities of BUPRANOLOL.


betaxolol may increase the bradycardic activities of digitoxin.


Dronedarone may increase the bradycardic activities of CARTEOLOL.


tizanidine may increase the bradycardic activities of Lanreotide.


Nebivolol may increase the bradycardic activities of Pasireotide.


penbutolol may increase the bradycardic activities of rivastigmine.


pyridostigmine may increase the bradycardic activities of practolol.


galanthamine may increase the bradycardic activities of donepezil.


BISOPROLOL may increase the bradycardic activities of rivastigmine.


pyridostigmine may increase the bradycardic activities of penbutolol.


Bevantolol may increase the bradycardic activities of deslanoside.


SUFENTANIL may increase the bradycardic activities of carvedilol.


LEVOBUNOLOL may increase the bradycardic activities of ouabain.


Regorafenib may increase the bradycardic activities of ESMOLOL.


ambenonium may increase the bradycardic activities of Nebivolol.


Bretylium may increase the bradycardic activities of Lanreotide.


Demecarium may increase the bradycardic activities of carvedilol.


GALLAMINE TRIETHIODIDE may increase the bradycardic activities of BUPRANOLOL.


LEVOBUNOLOL may increase the bradycardic activities of Fingolimod.


Tofacitinib may increase the bradycardic activities of carvedilol.


Dronedarone may increase the bradycardic activities of atenolol.


galanthamine may increase the bradycardic activities of practolol.


physostigmine may increase the bradycardic activities of BOPINDOLOL.


ambenonium may increase the bradycardic activities of Arotinolol.


NEOSTIGMINE may increase the bradycardic activities of celiprolol.


acebutolol may increase the bradycardic activities of Lanreotide.


donepezil may increase the bradycardic activities of timolol.


mefloquine may increase the bradycardic activities of BOPINDOLOL.


propranolol may increase the bradycardic activities of ouabain.


Bretylium may increase the bradycardic activities of betaxolol.